Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York on Wednesday, June 7, 2017 at 8 a.m. ET.
A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website for 30 days.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex® and GLAAS®. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
